(Q38777610)

6 September 2017

Improving Systemic Chemotherapy for Bladder Cancer (English)

1 reference

6 September 2017

1 reference

Tracy L Rose

1

1 reference

PubMed ID

26984414

6 September 2017

Matthew I Milowsky

series ordinal

2

1 reference

6 September 2017

1 May 2016

1 reference

6 September 2017

Current Oncology Reports

1 reference

6 September 2017

18

1 reference

6 September 2017

27

1 reference

6 September 2017

5

1 reference

https://scigraph.springernature.com/pub.10.1007/s11912-016-0512-2

6 September 2017

0 references

cites work

Cancer statistics, 2015

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0512-2

Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0512-2

Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0512-2

Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0512-2

International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0512-2

Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0512-2

A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0512-2

Relative efficacy of perioperative gemcitabine and cisplatin versus methotrexate, vinblastine, adriamycin, and cisplatin in the management of locally advanced urothelial carcinoma of the bladder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0512-2

Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0512-2

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0512-2

Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0512-2

Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0512-2

Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0512-2

The COXEN principle: translating signatures of in vitro chemosensitivity into tools for clinical outcome prediction and drug discovery in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0512-2

Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0512-2

Trends in the utilization of neoadjuvant chemotherapy in muscle-invasive bladder cancer: results from the National Cancer Database.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0512-2

Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0512-2

Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0512-2

Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0512-2

Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0512-2

Radiotherapy with and without cisplatin in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0512-2

Long-term outcome of radiation-based conservation therapy for invasive bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0512-2

Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemoth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0512-2

Trimodality treatment and selective organ preservation for bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0512-2

Combined-modality therapy with gemcitabine and radiation therapy as a bladder preservation strategy: long-term results of a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0512-2

A single institution experience with concurrent capecitabine and radiation therapy in weak and/or elderly patients with urothelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0512-2

Phase II study of gemcitabine and cisplatin in patients with advanced or metastatic bladder cancer: long-term follow-up of a 3-week regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0512-2

Three-week versus four-week schedule of cisplatin and gemcitabine: results of a randomized phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0512-2

Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0512-2

Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0512-2

Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0512-2

Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0512-2

Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0512-2

Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0512-2

Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0512-2

Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0512-2

Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0512-2

Do patients with advanced urothelial carcinoma benefit from weekly paclitaxel chemotherapy? A GETUG phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0512-2

Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0512-2

Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0512-2

Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0512-2

A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0512-2

Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0512-2

Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0512-2

Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0512-2

A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0512-2

Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0512-2

Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0512-2

Combination chemotherapy with gemcitabine and ifosfamide as second-line treatment in metastatic urothelial cancer. A phase II trial conducted by the Hellenic Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0512-2

Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0512-2

The safety and efficacy of single-agent pemetrexed in platinum-resistant advanced urothelial carcinoma: a large single-institution experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0512-2

Comprehensive molecular characterization of urothelial bladder carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0512-2

Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0512-2

A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: clinical and pathological results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0512-2

A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0512-2

Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0512-2

A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0512-2

Fibroblast growth factor receptor 3 mutations in bladder tumors correlate with low frequency of chromosome alterations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0512-2

Phase II study of sunitinib in patients with metastatic urothelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0512-2

Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0512-2

A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0512-2

Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0512-2

Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0512-2

Phase II study of everolimus in metastatic urothelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0512-2

Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0512-2

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0512-2

Genetic basis for clinical response to CTLA-4 blockade in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0512-2

Signatures of mutational processes in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0512-2

Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0512-2

Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0512-2

Radiotherapy with or without Chemotherapy in Muscle-Invasive Bladder Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0512-2

Advanced Bladder Cancer (Stages pT3b, pT4a, pN1 and pN2): Improved Survival after Radical Cystectomy and 3 Adjuvant Cycles of Chemotherapy. Results of a Controlled Prospective Study

21 January 2018

1 reference

12 December 2020

Gemcitabine plus Cisplatin versus Gemcitabine plus Carboplatin as First-Line Chemotherapy in Advanced Transitional Cell Carcinoma of the Urothelium: Results of a Randomized Phase 2 Trial

1 reference

12 December 2020

Improved 5-Factor Prognostic Classification of Patients Receiving Salvage Systemic Therapy for Advanced Urothelial Carcinoma

1 reference

12 December 2020

Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma.

1 reference

12 December 2020

Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers

1 reference

12 December 2020

Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy

1 reference

12 December 2020

The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial

1 reference

12 December 2020

Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results

1 reference

12 December 2020

Radiochemotherapy with cisplatin and 5-fluorouracil after transurethral surgery in patients with bladder cancer

1 reference

12 December 2020

1 reference

12 December 2020

Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer

1 reference

12 December 2020

Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer

1 reference

12 December 2020

Preliminary results of simultaneous radiochemotherapy with paclitaxel for urinary bladder cancer

1 reference

12 December 2020

Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium

1 reference

12 December 2020

A study of split-dose cisplatin-based neo-adjuvant chemotherapy in muscle-invasive bladder cancer

1 reference

12 December 2020

Radiation therapy and concomitant paclitaxel/carboplatin chemotherapy for muscle invasive transitional cell carcinoma of the bladder: a well-tolerated combination

1 reference

12 December 2020

Neoadjuvant Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With Pegfilgrastim Support in Muscle-Invasive Urothelial Cancer: Pathologic, Radiologic, and Biomarker Correlates

1 reference

12 December 2020

Treatment of invasive bladder cancer by cisplatin and radiation in patients unsuited for surgery

1 reference

12 December 2020

Trends in the use of perioperative chemotherapy for localized and locally advanced muscle-invasive bladder cancer: a sign of changing tides

1 reference

12 December 2020

Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: a prospective study

1 reference

12 December 2020

Topotecan in previously treated advanced urothelial carcinoma: an ECOG phase II trial

1 reference

12 December 2020

Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists

1 reference

12 December 2020

10.1007/S11912-016-0512-2

Identifiers

DOI

1 reference

PubMed ID

26984414

Dimensions Publication ID

6 September 2017

0 references

1 reference

PubMed ID

26984414